S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

Karuna Therapeutics Stock Price, News & Analysis (NASDAQ:KRTX)

$205.48
-0.77 (-0.37%)
(As of 12/8/2023 ET)
Compare
Today's Range
$200.00
$206.18
50-Day Range
$161.01
$208.80
52-Week Range
$158.38
$245.00
Volume
555,033 shs
Average Volume
269,633 shs
Market Capitalization
$7.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$259.38

Karuna Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
26.2% Upside
$259.38 Price Target
Short Interest
Bearish
5.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Karuna Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.76 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.31) to ($11.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

356th out of 946 stocks

Pharmaceutical Preparations Industry

126th out of 408 stocks


KRTX stock logo

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Stock Price History

KRTX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
Q3 2023 Karuna Therapeutics Inc Earnings Call
See More Headlines
Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$259.38
High Stock Price Target
$318.00
Low Stock Price Target
$209.00
Potential Upside/Downside
+26.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-276,340,000.00
Net Margins
-2,795.96%
Pretax Margin
-6,661.80%

Debt

Sales & Book Value

Annual Sales
$5.93 million
Book Value
$32.78 per share

Miscellaneous

Free Float
32,747,000
Market Cap
$7.75 billion
Optionable
Not Optionable
Beta
1.11
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Andrew Craig MillerDr. Andrew Craig Miller (Age 41)
    Co-Founder & COO
    Comp: $835.4k
  • Dr. Steven M. Paul M.D. (Age 72)
    President of Research and Development, Chief Scientific Officer & Director
    Comp: $1.32M
  • Dr. Stephen K. BrannanDr. Stephen K. Brannan (Age 67)
    Chief Medical Officer
    Comp: $751.75k
  • Mr. William Meury (Age 55)
    President, CEO & Director
  • Mr. Jason Parker Brown
    Chief Financial Officer
  • Ms. Alexis Smith
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Mia Kelley J.D.
    Vice President of Legal Affairs
  • Mr. Frank Truslow
    Senior Vice President of Corporate Development
  • Mr. Jonathan Rosin
    Chief Human Resources Officer
  • Dr. Alan Breier
    Chair of Scientific Advisory Board & Chief Clinical Advisor














KRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KRTX shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price target for 2024?

12 equities research analysts have issued 1 year price objectives for Karuna Therapeutics' shares. Their KRTX share price targets range from $209.00 to $318.00. On average, they predict the company's share price to reach $259.38 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2023?

Karuna Therapeutics' stock was trading at $196.50 at the beginning of 2023. Since then, KRTX stock has increased by 4.6% and is now trading at $205.48.
View the best growth stocks for 2023 here
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) announced its earnings results on Thursday, November, 2nd. The company reported ($3.16) EPS for the quarter, missing analysts' consensus estimates of ($2.74) by $0.42. Karuna Therapeutics had a negative net margin of 2,795.96% and a negative trailing twelve-month return on equity of 29.58%.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Wellington Management Group LLP (3.41%), Pivotal bioVenture Partners Investment Advisor LLC (2.11%), Rock Springs Capital Management LP (1.34%), Invesco Ltd. (0.97%) and Eventide Asset Management LLC (0.90%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KRTX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -